Investment Rating - The investment rating for the company is "Accumulate" with a target price of 177.30 CNY [6][12]. Core Insights - The company, WuXi AppTec, is a leading global CRDMO player, with its 2025 performance exceeding guidance, showing a significant profit margin increase. The Tides business is strong, with a backlog of orders increasing by 28% by the end of 2025, and a projected revenue growth of 18-22% for 2026 [2][12]. Financial Summary - Total revenue for 2025 was 45,456 million CNY, a year-on-year increase of 15.8%, surpassing the revised guidance. The net profit attributable to shareholders reached 19,151 million CNY, up 102.6% year-on-year. The adjusted Non-IFRS net profit was 14,960 million CNY, reflecting a 41.3% increase [4][12]. - The company forecasts revenues of 52,405 million CNY, 60,176 million CNY, and 66,900 million CNY for 2026, 2027, and 2028, respectively, with growth rates of 15.3%, 14.8%, and 11.2%. The net profit attributable to shareholders is expected to be 17,638 million CNY, 20,442 million CNY, and 22,375 million CNY for the same years, with growth rates of -7.9%, 15.9%, and 9.5% [12][13]. - The adjusted Non-IFRS gross margin improved to 48.2%, a year-on-year increase of 6.6 percentage points, driven by higher capacity utilization and an increase in high-margin business [12]. Business Performance - The chemical business generated revenue of 36,470 million CNY, a 25.5% year-on-year increase. The small molecule CDMO pipeline expanded, with revenue from small molecule D&M business reaching 19,920 million CNY, up 11.4% year-on-year [12]. - The Tides business saw revenue of 11,370 million CNY, a remarkable growth of 96% year-on-year, with a backlog of orders increasing by 20.2%. The number of clients for TIDES D&M services rose by 25%, and the number of service molecules increased by 45% [12].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 177.30 CNY [6][12]. Core Insights - The company, WuXi AppTec, is a leading global CRDMO player, with its 2025 annual performance exceeding guidance, showing a significant profit margin increase. The Tides business is strong, with a backlog of orders increasing by 28% as of the end of 2025, and a projected revenue growth of 18-22% for 2026 [2][12]. Financial Summary - Total revenue for 2025 was 45,456 million CNY, a year-on-year increase of 15.8%, surpassing the revised revenue guidance. The net profit attributable to shareholders was 19,151 million CNY, up 102.6% year-on-year. The adjusted Non-IFRS net profit was 14,960 million CNY, reflecting a 41.3% increase [4][12]. - The company expects revenues for 2026 to be between 52,405 million CNY and 53,000 million CNY, with a growth rate of 15.3% [12]. - The gross margin for adjusted Non-IFRS increased to 48.2%, up 6.6 percentage points year-on-year, driven by improved capacity utilization and a higher proportion of high-margin businesses [12]. Business Segments - The chemical business generated revenue of 36,470 million CNY in 2025, a 25.5% increase. The small molecule CDMO pipeline continues to expand, with 199,200 million CNY in revenue, an 11.4% increase, and a total of 3,452 molecules in the pipeline [12]. - The Tides business saw revenue of 11,370 million CNY in 2025, a remarkable 96% increase, with a backlog of orders growing by 20.2% [12]. Future Projections - For 2026-2028, the company forecasts revenues of 52,405 million CNY, 60,176 million CNY, and 66,900 million CNY, with growth rates of 15.3%, 14.8%, and 11.2% respectively. The net profit attributable to shareholders is projected to be 17,638 million CNY, 20,442 million CNY, and 22,375 million CNY for the same years, with growth rates of -7.9%, 15.9%, and 9.5% respectively [12][13].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a strong recovery in the biopharmaceutical sector, with significant growth in the "WuXi" companies, indicating a return to a prosperous cycle driven by increased demand and order expansion [4][34] - The report emphasizes the structural growth in the industry, particularly in preclinical services and small molecule CDMO, which are expected to accelerate in 2026 [5][36] Summary by Sections 1. "WuXi" Companies Performance - WuXi AppTec achieved a revenue of 45.46 billion RMB in 2025, a year-on-year increase of 15.8%, with a net profit of 19.15 billion RMB, reflecting a 102.7% increase [13] - WuXi Biologics reported a revenue of 21.79 billion RMB, up 16.7%, and a net profit increase of 45.3% [18] - WuXi STA's revenue grew by 46.7%, with a net profit increase of 69.9%, indicating strong order growth and demand recovery [26] 2. Growth Outlook for 2026 - WuXi AppTec expects a revenue growth of 18-22% for its continuing operations in 2026, with capital expenditures projected to rise to 6.5-7.5 billion RMB [4][35] - WuXi Biologics anticipates a revenue increase of 13-17% in 2026, factoring in currency fluctuations [34] - WuXi STA aims for a CAGR of 30-35% from 2025 to 2030, indicating robust growth potential [34] 3. Structural Growth Trends - The preclinical CRO sector is showing signs of recovery, with WuXi AppTec's testing services returning to positive growth and significant order increases in preclinical services [5][34] - Small molecule CDMO is expected to accelerate growth in 2026, driven by increased demand for GLP-1 class drugs [36] - ADC/XDC/TIDES CDMO sectors are maintaining high growth rates, with WuXi STA projecting a 25% CAGR over the next five years [38] 4. Market Performance - The biopharmaceutical sector rose by 1.56% in March 2026, outperforming the CSI 300 index by 2.97 percentage points [39] - The medical R&D outsourcing sector saw the largest gains, while the blood products sector experienced the most significant decline [40]

Investment Rating - The report indicates a positive outlook for the company, with management expecting revenue growth of 18%-22% in 2026 [1][17]. Core Insights - The company, WuXi AppTec, reported a revenue of 45.46 billion RMB in 2025, representing a year-on-year growth of 15.8%, with core business revenue reaching 43.42 billion RMB, up 21.4% [4][7]. - The net profit attributable to shareholders was 19.15 billion RMB, a significant increase of 102.6%, although this included investment gains from asset disposals [7]. - The adjusted net profit under Non-IFRS standards was 14.96 billion RMB, reflecting a 41.3% year-on-year increase, with an adjusted net profit margin of approximately 32.9%, up 5.9 percentage points [7][23]. Revenue Breakdown - The chemical business was the standout performer, generating 36.47 billion RMB, accounting for 80% of total revenue, and growing by 25.5% year-on-year [9]. - The TIDES business (oligonucleotides and peptides) saw a remarkable revenue increase of 96% to 11.37 billion RMB, driven by the rising demand for GLP-1 class drugs [10][12]. - The company had an order backlog of 58 billion RMB at the end of the year, marking a 28.8% increase [14]. Market Outlook - The global pharmaceutical R&D spending is projected to grow from 277.6 billion USD in 2024 to 373.1 billion USD by 2029, with the outsourcing ratio expected to rise [20]. - The global pharmaceutical R&D outsourcing market is anticipated to expand from 136.5 billion USD in 2024 to 239.5 billion USD by 2029, with a compound annual growth rate of approximately 11.9% [21]. Financial Performance - The company maintained a gross margin above 40% over the past three years, achieving a gross margin of 47.6% in 2025, an increase of 6.2 percentage points [23]. - Operating cash flow reached 17.2 billion RMB, and free cash flow was 11.7 billion RMB, both showing year-on-year growth of approximately 38.7% and 38.8% respectively [25]. - The company expects capital expenditures of 6.5 to 7.5 billion RMB in 2026, with adjusted free cash flow projected at 10.5 to 11.5 billion RMB [27].

Investment Rating - The investment rating for WuXi AppTec (603259.SH) is maintained at "Buy" [1] Core Insights - WuXi AppTec has exceeded its annual guidance, with a strong growth forecast for small molecule CDMO services accelerating in 2026 [1] - The company achieved a record revenue of 454.56 billion yuan in 2025, representing a year-on-year growth of 15.8%, with a net profit of 191.51 billion yuan, up 102.7% [3][4] - The adjusted Non-IFRS net profit for 2025 was 149.6 billion yuan, reflecting a 41.3% increase, with a net profit margin of 32.9%, up 5.9 percentage points year-on-year [3] - The company anticipates revenue for 2026 to be between 513-530 billion yuan, with a year-on-year growth of 18-22% for ongoing operations [5] Financial Summary - In 2025, the chemical business generated revenue of 364.7 billion yuan, a 25.5% increase year-on-year, while the small molecule D&M business revenue was 199.2 billion yuan, up 11.4% [4] - The TIDES business saw remarkable growth, achieving revenue of 113.7 billion yuan, a 96.0% increase year-on-year [4] - The company’s total market capitalization is approximately 2619.44 billion yuan, with a circulating market capitalization of 2171.29 billion yuan [1] - The projected earnings per share (EPS) for 2026-2028 are 6.14, 7.60, and 9.35 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 14.3, 11.6, and 9.4 [3][7]

Investment Rating - The investment rating for WuXi AppTec (603259.SH) is maintained at "Buy" [1] Core Insights - WuXi AppTec has exceeded its annual guidance, with a strong growth forecast for small molecule CDMO services accelerating in 2026 [1][3] - The company achieved a record revenue of 454.56 billion yuan in 2025, representing a year-on-year growth of 15.8%, with a significant increase in net profit [3][4] - The ongoing demand recovery and the expected acceleration in small molecule CDMO business have led to upward revisions in profit forecasts for 2026 and 2027 [3][4] Financial Performance Summary - In 2025, the company reported revenue of 454.56 billion yuan, a 15.8% increase year-on-year, and a net profit of 191.51 billion yuan, up 102.7% [3][4] - The adjusted Non-IFRS net profit for 2025 was 149.6 billion yuan, reflecting a 41.3% increase, with a net profit margin of 32.9%, up 5.9 percentage points year-on-year [3] - The company expects revenue for 2026 to be between 513-530 billion yuan, with a year-on-year growth of 18-22% for ongoing operations [5] Business Segment Performance - The chemical business generated revenue of 364.7 billion yuan in 2025, a year-on-year increase of 25.5%, with the small molecule D&M business contributing 199.2 billion yuan, up 11.4% [4] - The TIDES business saw remarkable growth, achieving revenue of 113.7 billion yuan in 2025, a 96.0% increase year-on-year [4] - The company’s testing business and biological services also showed positive growth, with revenues of 40.4 billion yuan and 26.8 billion yuan respectively in 2025 [5] Earnings Forecast - The profit forecasts for 2026, 2027, and 2028 are set at 183.24 billion yuan, 226.74 billion yuan, and 278.86 billion yuan respectively, with corresponding EPS of 6.14 yuan, 7.60 yuan, and 9.35 yuan [3][7] - The current stock price corresponds to a P/E ratio of 14.3 for 2026, 11.6 for 2027, and 9.4 for 2028, indicating potential value [3][7]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [2][8]. Core Insights - The company reported a revenue of 454.6 billion yuan for 2025, representing a year-on-year growth of 15.8%, and a net profit attributable to shareholders of 191.5 billion yuan, which is a significant increase of 102.6% [4][8]. - The Chemistry business showed stable growth with a revenue of 364.7 billion yuan in 2025, up 25.5%, while the TIDES business experienced remarkable growth, generating 113.7 billion yuan, a 96.0% increase [5][8]. - The company has a strong order backlog of 580 billion yuan, reflecting a year-on-year increase of 28.8% as of the end of 2025, with guidance for 2026 indicating an expected revenue of 513-530 billion yuan, representing a growth of 18-22% [7][8]. Summary by Relevant Sections Financial Performance - For Q4 2025, the company achieved a revenue of 126.0 billion yuan, up 9.2%, and a net profit of 70.8 billion yuan, which is a 142.5% increase [4]. - The overall gross margin for 2025 was 48.2%, an increase of 6.6 percentage points, while the Non-IFRS net profit margin was 32.9%, up 5.9 percentage points [7]. Business Segments - The Testing business generated 40.4 billion yuan in revenue for 2025, a growth of 4.7%, but faced margin pressure with a gross margin of 30.5%, down 5.7 percentage points [6]. - The Biology business reported a revenue of 26.8 billion yuan, up 5.5%, with a gross margin of 37.0%, down 1.9 percentage points [6]. Future Projections - Revenue projections for 2026, 2027, and 2028 are estimated at 521.6 billion yuan, 605.9 billion yuan, and 694.5 billion yuan, respectively, with year-on-year growth rates of 14.7%, 16.2%, and 14.6% [8][11]. - The forecasted net profit for 2026 is 163.9 billion yuan, reflecting a decrease of 14.4% year-on-year, followed by increases of 17.7% and 16.1% in the subsequent years [8][11].

Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec, indicating a positive outlook for the company's stock performance relative to the benchmark index [4]. Core Insights - WuXi AppTec exceeded its annual guidance, achieving record high performance in 2025 with a revenue of 45.456 billion yuan, a year-on-year increase of 15.8%. The adjusted net profit attributable to shareholders reached 14.96 billion yuan, up 41.3% year-on-year [4][5]. - The company has a strong order backlog of 58 billion yuan, reflecting a year-on-year growth of 28.8%. The TIDES business significantly contributed to the growth of the chemical segment, with a revenue increase of 96% year-on-year [4][5]. - The company expects a revenue forecast for 2026 to be between 51.3 billion and 53 billion yuan, with a year-on-year growth of 18-22% for its continuing operations [4][5]. Financial Performance Summary - In 2025, WuXi AppTec's revenue was 45.456 billion yuan, with a gross margin of 47.6%, an increase of 6.16 percentage points year-on-year. The net profit attributable to shareholders was 19.151 billion yuan, reflecting a 102.6% increase year-on-year [4][5]. - The company projects revenues of 52.28 billion yuan for 2026, with a profit growth rate of -8.6% due to high base effects from 2025 [5][6]. - The report highlights a significant improvement in profitability metrics, with a sales net margin of 42.53%, up 18.15 percentage points year-on-year [4][5]. Business Segment Performance - The chemical business generated 36.47 billion yuan in revenue, a 25.5% increase year-on-year, while the TIDES business alone contributed 11.37 billion yuan, marking a 96% increase [4][5]. - Revenue from U.S. clients grew by 34.3% to 31.25 billion yuan, while revenue from Europe and China saw slight declines [4][5]. - The report emphasizes the company's strong position in the global supply chain, unaffected by recent geopolitical tensions and trade conflicts [4][5]. Future Outlook - WuXi AppTec aims to enhance its technological capabilities and operational efficiency, with capital expenditures projected to reach 6.5-7.5 billion yuan in 2026 [4][5]. - The company anticipates adjusted free cash flow to be between 10.5 billion and 11.5 billion yuan in 2026, indicating strong cash generation potential [4][5]. - The report forecasts continued growth in the CRDMO sector, supported by a robust pipeline and global scale effects, positioning WuXi AppTec to lead the CXO industry [4][5].

Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec, indicating a positive outlook for the company's stock performance relative to the benchmark index [4]. Core Insights - WuXi AppTec achieved a record high in performance for the year 2025, with total revenue reaching 454.56 billion yuan, a year-on-year increase of 15.8%. The adjusted non-IFRS net profit was 14.96 billion yuan, up 41.3%, while the net profit attributable to shareholders was 19.15 billion yuan, reflecting a significant increase of 102.65% [4][5]. - The company reported a strong order backlog of 58 billion yuan, a year-on-year growth of 28.8%, driven by the TIDES business, which saw a revenue increase of 96% to 11.37 billion yuan [4][5]. - The revenue contribution from U.S. clients grew by 34.3% to 31.25 billion yuan, while European revenue decreased by 4% [4][5]. - For 2026, WuXi AppTec expects total revenue to be between 513 billion and 530 billion yuan, with a year-on-year growth of 18-22% in continuing operations [4][5]. Financial Performance Summary - In 2025, the company achieved a gross margin of 47.64%, an increase of 6.16 percentage points year-on-year, and a net profit margin of 42.53%, up 18.15 percentage points [4][5]. - The projected financials for 2026 include total revenue of 52.28 billion yuan, with a growth rate of 15%, and a net profit of 17.49 billion yuan, reflecting a decrease of 8.6% [5][6]. - The company’s EBITDA for 2025 was 27.87 billion yuan, with expectations for continued growth in subsequent years [7].

Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6][20] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][21] - The adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [10] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [11] - TIDES revenue nearly doubled, growing 96% year-over-year to RMB 11.37 billion, with a backlog growth of 20.2% [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [7] - Europe and China experienced declines due to fluctuations in project delivery timing [7] Company Strategy and Development Direction - The company remains focused on its integrated CRDMO core business, aiming to enhance global capabilities and operational efficiency [24] - WuXi AppTec plans to maintain a cash dividend distribution plan totaling RMB 5.7 billion in 2026, with a 30% annual cash dividend payout ratio [26] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining rapid business growth, expecting total revenue to reach RMB 51.3 billion to RMB 53 billion in 2026, with continuing operations revenue growing 18%-22% year-over-year [24] - The company is closely monitoring geopolitical situations and their potential impact on operations, emphasizing a mature and diversified procurement network [32][60] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [8] - The company completed 741 quality audits and inspections in 2025, maintaining high standards for quality and compliance [9] Q&A Session Summary Question: Impact of currency exchange on guidance - Management acknowledged the impact of FX movements but emphasized strong visibility in their CRDMO business model [30] Question: Geopolitical impact on margins - Management noted that while there are potential risks to raw material costs, they have not seen direct impacts on operations [32] Question: TIDES CapEx and future modalities - Management indicated that while peptide demand remains high, they are also seeing growth in oligonucleotides and complex small molecules [34] Question: Client outsourcing strategy changes - Management stated that large pharma continues to manufacture internally but they remain committed to improving capabilities and providing services [36] Question: Current utilization rate of small molecule capacity - Management highlighted their ability to provide high-quality data, which drives business for their Biology and Testing segments [38] Question: FDA's new trial requirements - Management believes that regulatory streamlining will benefit patients and potentially increase demand for drug substances [40] Question: Positioning in oral small molecule GLP-1 CDMO business - Management confirmed strong growth in the small molecule sector, particularly in GLP-1 drugs [47] Question: Revenue breakdown and geographical mix - Management noted strong growth across all regions, with a focus on customer needs driving geographic revenue growth [49][50] Question: Sustainability of TIDES growth - Management expressed confidence in sustained growth due to a robust pipeline and increasing demand for their products [54] Question: Timeline for new facility contributions - Management stated that new facilities in China can become operational in less than 12 months [57] Question: Impact of Middle East situation on investments - Management reassured that their long-term strategy remains unchanged despite geopolitical tensions [59] Question: Confidence in new orders and revenue guidance - Management expressed confidence in converting backlog into revenue and maintaining growth trajectory [65] Question: WuXi AppTec's position on the 1260H list - Management stated they are confident WuXi AppTec will not be included in the list and will continue to monitor the situation [70]